Tesamorelin Stability: How It Degrades and How to Slow It

Lyophilised tesamorelin is stable for years when sealed, dry and cold, but in solution it is one of the shorter-lived research peptides, because three specific residues react with water and oxygen. Asparagine 8 deamidates, aspartate 3 isomerises or cleaves, and methionine 27 oxidises, and each of these changes sharply reduces activity in the GHRH family.

These routes are well characterised because native GHRH(1-44) amide was studied intensively. Tesamorelin keeps that native sequence unchanged from residue 1 to 44; its only modification is the trans-3-hexenoyl cap on tyrosine 1. That cap blocks enzymatic clipping in plasma (Ferdinandi, Basic and Clinical Pharmacology and Toxicology, 2007) but does not alter the chemistry at residues 3, 8 and 27, so the published GHRH degradation work applies directly.

Route 1: deamidation at asparagine 8

Asparagine 8 sits next to serine 9, a pairing that allows the backbone nitrogen to attack the side chain and form a cyclic succinimide. The ring opens to aspartate or to the unnatural beta (iso) aspartate. In human GRF this happened at pH 5 and above, giving beta-Asp8 and Asp8 in roughly a 4:1 ratio (Bongers, International Journal of Peptide and Protein Research, 1992). The consequences are large: a GRF analogue’s beta-Asp8 product was 400 to 500 times less potent than the parent, and swapping asparagine 8 for serine extended the analogue’s half-life in pH 7.4 buffer at 37 °C from 202 to 1,550 hours (Friedman, International Journal of Peptide and Protein Research, 1991). Structure helps a little: when the region around Asn8 is helical, deamidation slows (Stevenson, International Journal of Peptide and Protein Research, 1993).

Route 2: aspartate 3

Aspartate 3, followed by alanine 4, is the second weak point. Below about pH 4, where the Asp3 side chain is protonated, the Asp3-Ala4 bond cleaves to give the 4-44 fragment. Above pH 4, isomerisation to beta-Asp3 dominates (Bongers, International Journal of Peptide and Protein Research, 1992). Both products lost most of their in vitro potency. The same study found no degradation at aspartate 25 or asparagine 35 under its conditions, so the reactive sites are concentrated at the front of the chain.

Route 3: oxidation of methionine 27

Methionine 27 is the only sulphur-containing residue. In aqueous solution it oxidises to methionine sulfoxide, which greatly reduces bioactivity; this is why many engineered GHRH analogues replace Met27 with leucine (Campbell, Peptides, 1994). Tesamorelin keeps the native methionine, so dissolved oxygen, trace metals, peroxides and light all shorten its life in a vial. With no cysteine or tryptophan, the two tyrosines (1 and 10) are only a minor, light-driven concern.

The pH window

Because the routes pull in opposite directions, GHRH is most stable between pH 4 and 5 (Bongers, International Journal of Peptide and Protein Research, 1992). Lower pH favours Asp3 cleavage; higher pH accelerates Asn8 deamidation. The acetate salt dissolved in bacteriostatic water gives a mildly acidic solution, which is a reasonable place to be. Neutral buffers such as phosphate-buffered saline sit on the faster deamidation side, which is one reason a supplier advises against keeping a buffered aqueous solution for more than a day (Cayman Chemical, product information).

Lyophilised versus reconstituted

Every route above needs water. In a dry, sealed cake, molecular mobility is too low for succinimide formation or meaningful oxidation, which is why one supplier rates the solid at least 4 years at -20 °C (Cayman Chemical, product information). Once mixed, the clock is short: the approved formulation is discarded 7 days after mixing (US prescribing information, 2025), and our guidance applies the same 7-day limit to a research vial kept at 2 to 8 °C in the dark. The full windows are on how long does tesamorelin last.

Temperature, light and freeze-thaw

• Temperature. Deamidation and oxidation both speed up with warmth. A mixed vial lives in the fridge, not on the bench.
• Light. The approved product is kept in its box for light protection (US prescribing information, 2025). Light generates reactive oxygen species that target Met27 and the tyrosines, so research vials stay boxed or in an opaque container.
• Freeze-thaw. The dry solid tolerates the freezer. A mixed solution is never frozen: ice formation concentrates the peptide between crystals and drives aggregation of its helical region, and both approved formulations say not to freeze the mixed solution.

What visible changes mean

A correctly mixed solution is clear and colourless. Deamidation and oxidation are invisible, so a clear vial past 7 days is still past its window. Visible changes point to physical instability instead:

• Haze that does not clear after 10 to 15 minutes: self-association of the amphipathic helix, often after shaking or warm storage.
• Gel or stringy strands: extended aggregation, usually from high concentration plus agitation. See why peptides gel or go cloudy.
• Particles or flakes: aggregated or contaminated material. The vial is discarded.
• Any yellow tint: oxidative change. Discard.

Concentration choices are on the tesamorelin reconstitution page, and dissolution behaviour is on the solubility page.

Sources: Bongers J et al., Int J Pept Protein Res 1992 (PMID 1428526); Friedman AR et al., Int J Pept Protein Res 1991 (PMID 1904406); Stevenson CL et al., Int J Pept Protein Res 1993 (PMID 8307680); Campbell RM et al., Peptides 1994 (PMID 7937325); Ferdinandi ES et al., Basic Clin Pharmacol Toxicol 2007 (PMID 17214611); Cayman Chemical, tesamorelin (acetate) item 42498 product information; US prescribing information for tesamorelin, revised 2025.